Melanoma of unknown primary: favorable survival persists in the immunotherapy era. Maharaj S, Jain N, Al Bawaliz A, Miller D, et al. Int J Dermatol 2022 Aug 28. doi: 10.1111/ijd.16419.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Maharaj S, Jain N, Al Bawaliz A, Miller D, et al. Melanoma of unknown primary: favorable survival persists in the immunotherapy era. Int J Dermatol 2022 Aug 28. doi: 10.1111/ijd.16419.
PMID: 36030543